Virgin Voyages Sets Sights on the Med for Second Ship ‘Valiant Lady’ Launching 3 Exhilarating 7-night Itineraries From Barcelona With Overnights in Ibiza
Virgin Voyages, the new lifestyle brand shaking up the travel industry, announced their second ship will be called ‘Valiant Lady’ and that she will sail 7-night Mediterranean itineraries out of Barcelona, Spain when she debuts in May 2021. Bookings for the three feature itineraries, that all offer overnight and late-night stops across some of the hottest destinations in France, Italy and Spain, will open December 19, 2019.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005362/en/
Virgin Voyages Sets Sights on the Med for Second Ship ‘Valiant Lady’ (Graphic: Business Wire)
“We are thrilled to unveil the name of our second ship - Valiant Lady - and to deliver on our commitment to offer travelers a sea change in how they can experience cruising in this fantastic part of the world. Our Sailors will fall in love with the places we go and the moments and memories they will be able to create on our gorgeous ship. After all, there is no better way to sail the seven seas than doing it the Virgin way,” said Tom McAlpin, CEO of Virgin Voyages.
2021 Summers on the Med with a home in Barcelona
Valiant Lady will dock just steps from Las Ramblas at the World Trade Center Barcelona, positioning Sailors as close to the heart of this stunning departure-port-city as possible. This prime location, usually reserved by luxury liners and mega-yachts, gives walking access to the dynamic and diverse neighborhoods of Poble Sec, el Raval, Barri Gotic, Port Vell and the famed urban beach of La Barceloneta. With a weekly Sunday sail away, Sailors will enjoy extra time in Barcelona and be able to take advantage of many different flight options. Virgin Voyages is partnering with Global Ports Holding, the world’s leading independent cruise port operator, to prepare for Valiant Lady’s arrival in early summer 2021.
Open for bookings December 2019, 7 night sailings start May 2021 and feature an overnight in Ibiza
The Med, home to some of the world’s best beach clubs, cultural experiences, restorative spas, yacht clubs and nightlife, is a perfect choice for Virgin Voyages. Valiant Lady will sail 3 different itineraries with truly breathtaking ports of call.
- Itinerary 1 includes the exotic delights of Barcelona, Ibiza, Monte Carlo, Marseille and Olbia
- Itinerary 2 includes a fantastic sampling of the Med featuring Barcelona, Ibiza, Toulon, Ajaccio, Marina di Carrara and Cagliari
- Itinerary 3 is a mostly Spanish immersion, stopping by Barcelona, Ibiza, Palma de Mallorca, Malaga and the British port of Gibraltar
Hearing Sailor and First Mates (travel partners) requests for later stays in ports, Virgin has delivered this on every itinerary. This means Sailors have the flexibility to make the most of their time in port and take in all that these destinations have to offer. Of particular note, every sailing features a Friday overnight stay in Ibiza, one of the most stunning and thrilling Balearic Islands. Whether it’s a blissed out beach club, a bohemian market, a serene spa, watching the stunning sunsets, or a late night out, there is no comparable place that offers the variety and style of this ultimate destination.
Introducing ‘Valiant Lady’
Virgin Voyages also revealed that the name ‘Valiant Lady’ was inspired by the Latin word valere and from the French origin, vaillant, meaning “bold”, “strong”, and “courageous." While historically, the image of women only graced the bows of ships to bring protection to a vessel, ‘Valiant Lady’ embodies the idea that women design, captain, lead and champion change in the maritime industry.
The Scarlet Lady’s sister ship ‘Valiant Lady’ will continue Virgin Voyages’ ‘Scarlet Squad’ program aimed at recruiting, supporting and mentoring female shipboard talent, and growing opportunities to access leadership roles in onboard areas such as marine, technical and hotel management that statistically show low numbers of female leadership.
All Virgin Voyages ships have been designed by a leading creative collective who are the brains behind some of the world’s most loved boutique hotel brands. The collective includes names like Design Research Studio (Tom Dixon), Roman & Williams and Concrete Amsterdam who have all been inspired by the brand’s design concept- the Modern Romance of Sailing and Mission to Redefine the Experience of a Vacation at Sea.
Future Sailors, First Mates and travel advisors are invited to check out Virgin Voyages by visiting www.virginvoyages.com or following @virginvoyages on Instagram, Facebook, Twitter or LinkedIn.
ABOUT VIRGIN VOYAGES
Virgin Voyages is a global lifestyle brand committed to creating the world’s most irresistible holidays. The brand currently has four ships on order with master shipbuilder Fincantieri and has operations in the US, UK and Europe. Virgin Voyages’ ships are designed to reflect a super yacht’s sleek luxury, featuring spaces designed by some of the top names in contemporary interiors. An Adult-by-Design sanctuary, the ships offer a dose of Vitamin Sea with well-being activated through a mix of high-energy moments coupled with relaxation and rejuvenation. Scarlet Lady will also feature never before seen entertainment and 20+ world-class intimate eateries on board. Virgin Voyages offers incredible value for its sailors with all restaurants, group fitness classes, soft drinks, and many more Virgin surprises included within the voyage fare. Scarlet Lady will sail from Miami to the Caribbean all year round from March 2020 and Valiant Lady will sail the Mediterranean from May 2021. The fleet's ships host more than 2,770 sailors and 1,160 amazing crew from around the world. Keep watch on virginvoyages.com for more updates.
FOLLOW VIRGIN VOYAGES:
Instagram: @virginvoyages
Facebook: @virginvoyages
Twitter: @virginvoyages
LinkedIn: Virgin Voyages
YouTube: Virgin Voyages
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005362/en/
Contact information
ALISON BROD MARKETING + COMMUNICATIONS
Virgin@alisonbrodmc.com
Virgin Voyages
Michelle Estevam, media@virginvoyages.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom